Market Place
Sourcing Support
UCB strikes $1.15B deal for cell therapy biotech Neurona
17 Apr 2026 //
FIERCE BIOTECH
UCB Unveils Latest Gmg Data At 2026 AAN Meeting
13 Apr 2026 //
PR NEWSWIRE
UCB Unveils High Skin Clearance Rates For BIMZELX In Psoriasis
27 Mar 2026 //
PR NEWSWIRE
UCB Investing $2B To Build Manufacturing Facility in Georgia
25 Mar 2026 //
BIOSPACE
Bimekizumab Outperforms Risankizumab In Psoriatic Arthritis Study
11 Mar 2026 //
PR NEWSWIRE
UCB enters TCE space with $1.1B Deal for Autoimmune Candidate
05 Mar 2026 //
PRESS RELEASE
Antengene and UCB Enter Global License Agreement for ATG-201
04 Mar 2026 //
PR NEWSWIRE
UCB Shares Leading Research at AES Annual Meeting
04 Dec 2025 //
PR NEWSWIRE
Bimzelx Data Show 3-Year Pain And Tunnel Resolution Gains in HS
31 Oct 2025 //
PR NEWSWIRE
Ucb to Present New gMG Data for Rystiggo and Zilbrysq
29 Oct 2025 //
PR NEWSWIRE
BIMZELX 3-Year Data Shows Sustained Control in Arthritis Cases
28 Oct 2025 //
PHARMIWEB
Bimzelx Three-Year Rheumatology Data at ACR 2025
25 Oct 2025 //
PR NEWSWIRE
Ucb Reports Positive First Patient Trial For Galvokimig
18 Sep 2025 //
PHARMAWEB
Bimzelx Shows Sustained Relief in Hidradenitis Suppurativa
17 Sep 2025 //
PR NEWSWIRE
UCB Expands BIMZELX® Campaign for Hidradenitis Patients
09 Jul 2025 //
PR NEWSWIRE
UCB Announces US Investment to Expand Biologics Capacity
12 Jun 2025 //
PR NEWSWIRE
Dapirolizumab Ph3 SLE Data Shows Less Fatigue & Disease Activity
12 Jun 2025 //
GLOBENEWSWIRE
BIMZELX® Three-Year Data at EULAR 2025 Shows Lasting Efficacy
11 Jun 2025 //
PR NEWSWIRE
Bimzelx 2-Year Data Shows HS Tunnel Elimination At AAD 2025
07 Mar 2025 //
PR NEWSWIRE
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness
14 Feb 2025 //
FIERCE PHARMA
UCB Announces Bimzelx 320 mg Single-Injection Now Available In U.S.
16 Jan 2025 //
PR NEWSWIRE
UCB partners with Ailux Biologics on Biologics AI Platform
09 Jan 2025 //
PR NEWSWIRE
Roche`s Prothena-partnered Parkinson`s prospect fails phase 2b
19 Dec 2024 //
FIERCE BIOTECH
UCB receives FDA approval for BIMZELX For hidradenitis suppurativa
21 Nov 2024 //
PRESS RELEASE
Dapirolizumab Pegol Ph 3 Data Shows Lupus Disease Activity Reduction
19 Nov 2024 //
GLOBENEWSWIRE
UCB blockbuster potential for Bimzelx with 3 new FDA approvals "
24 Sep 2024 //
FIERCE PHARMA
Biogen-UCB`s lupus drug meets main goal of late-stage trial
24 Sep 2024 //
PRESS RELEASE
FDA Accepts sBLA for BIMZELX for Moderate-to-Severe Hidradenitis Suppurativa
04 Apr 2024 //
PR NEWSWIRE
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S
03 Jan 2024 //
PR NEWSWIRE
UCB Announces U.S. Availability of BIMZELX® for Plaque Psoriasis
14 Nov 2023 //
PR NEWSWIRE
Phase 3 Data Presented at EADV 2023 Showed Bimekizumab Achieved Thresholds
12 Oct 2023 //
PR NEWSWIRE
FDA signs off on UCB`s myasthenia gravis drug Rystiggo
28 Jun 2023 //
FIERCE PHARMA
Novartis, UCB set to battle it out in inflammatory skin disease
10 Apr 2023 //
FIERCE PHARMA
Bimekizumab PIII Data in Hidradenitis Suppurativa Shows Response over 48 Weeks
18 Mar 2023 //
PR NEWSWIRE
UCB to Present Eight Bimekizumab Abstracts at AAD 2023
16 Mar 2023 //
PR NEWSWIRE
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab PIII
18 Jan 2023 //
PR NEWSWIRE
